Future studies of low-activity PON1 phenotype subjects may reveal how PON1 protects against cardiovascular disease

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 23, Issue 8, 2003, Pages 1317-1318

  La Du, Bert N ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLDIALKYLPHOSPHATASE;

CARDIOVASCULAR DISEASE; EDITORIAL; ENZYME ACTIVITY; GENETIC POLYMORPHISM; HUMAN; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL;

ARYLDIALKYLPHOSPHATASE; CARDIOVASCULAR DISEASES; GENETIC MARKERS; HUMANS; POINT MUTATION; POLYMORPHISM, GENETIC;

EID: 0042233509     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000082600.42562.7F     Document Type: Editorial

References (9)

1. Jarvik GP, Hatsukami TS, Carlson C, Richter RJ, Jampsa R, Brophy VH, Margolin S, Rieder M, Nickerson D, Schellenberg GD, Heagerty PJ. Furlong CE. Paraoxonase activity, but not haplotype utilizing the linkage disequilibrium structure, predicts vascular disease. Arterioscler Thromb Vas Biol. 2003;23:1465-1471.
2. Jarvik GP, Jampsa R, Richter RJ, Carlson CS, Rieder MJ, Nickerson DA. Furlong CE. Novel paraoxonase (PON1) nonsense and missense mutations predicted by functional genomic assay of PON1 status. Pharmacogenetics. 2003;13:291-295.
3. Wang X, Fan Z, Huang J, Su S, Yu Q, Zhao J. Hui R, Yao Z. Shen Y, Qiang B, Gu D. Extensive association analysis between polymorphisms of PON gene cluster with coronary heart disease in Chinese Han population. Arterioscler Thromb Vasc Biol. 2003;23:328-334.
4. Marchesani M, Hakkarainen A, Tuomainen TP, Kaikkonen J, Pukkala E. Uimari P, Seppala E, Matikainen M, Kallioniemi OP. Schleutker J, Lehtimaki T, Salonen JT. New paraoxonase 1 polymorphism I102V and the risk of prostate cancer in Finnish men. J Natl Cancer Inst. 2003;95:812-818.
5. Navab M, Hama SY, Wagner AC, Hough G, Watson AD, Reddy ST, Van Lenten BJ, Laks H, Fogelman AM. Protective action of HDL-assocciated PON1 against LDL oxidation. In: Costa LG, Furlong CE, eds. Paraoxonase (PON1) in Health and Disease: Basic and Clinical Aspects. Boston, Mass: Kluwer Academic Publishers; 2002:125-136.
6. Mackness MI, Durrington PN, Mackness B. The Role of paraoxonase in lipid metabolism. In: Costa LG, Furlong CE, eds. Paraoxonase (PON1) in Health and Disease: Basic and Clinical Aspects. Boston, Mass: Kluwer Academic Publishers; 2002:79-92.
7. Costa LG, Furlong CE, eds. Paraoxonase (PON1) in Health and Disease: Basic and Clinical Aspects. Boston, Mass: Kluwer Academic Publishers; 2002.
8. Weiss KM, Buchanan AV. Evolution by phenotype: a biomedical perspective. Perspect Biol Med. 2003;46:159-182.
9. Shih DM, Reddy S, Lusis AJ. CHD and atherosclerosis: human epidemiological studies and transgenic mouse models. In: Costa LG, Furlong CE, eds. Paraoxonase (PON1) in Health Disease: Basic and Clinical Aspects. Boston, Mass: Kluwer Academic Publishers; 2002:93-123.